Table 1 Patient and disease characteristics 2008–2010 Cohort and 2011–2013 Cohort
2008–2010 Cohort: mRCC at the initial diagnosis (n = 621) | 2011–2013 Cohort: mRCC (n = 221) | |||
|---|---|---|---|---|
Sex - n (%) | ||||
Female | 213 | 34 % | 60 | 27 % |
Male | 408 | 66 % | 161 | 73 % |
Median age - yr (range) | 66 | 23–93 | 66 | 27–93 |
Histology - n (%) | ||||
Clear cell | 354 | 57 % | 152 | 69 % |
Othera | 267 | 43 % | 69 | 31 % |
WHO performance status - n (%) | ||||
0–1 | 430 | 69 % | 178 | 81 % |
2–4 | 191 | 31 % | 42 | 19 % |
Site of metastasis - n (%) | ||||
One | 206 | 33 % | 87 | 39 % |
more than one | 415 | 67 % | 134 | 61 % |
Liver metastasis - n (%) | ||||
No | 509 | 82 % | 175 | 79 % |
Yes | 112 | 18 % | 46 | 21 % |
Lung metastasis - n (%) | ||||
No | 173 | 28 % | 74 | 33 % |
Yes | 448 | 72 % | 147 | 67 % |
Bone metastasis - n (%) | ||||
No | 393 | 63 % | 158 | 71 % |
Yes | 228 | 37 % | 63 | 29 % |
Brain metastasis - n (%) | ||||
No | 571 | 92 % | 200 | 90 % |
Yes | 50 | 8 % | 16 | 7 % |
Haemoglobin - n (%) | ||||
Normal | 205 | 33 % | 85 | 38 % |
< LLN | 416 | 67 % | 136 | 62 % |
Neutrophil count - n (%) | ||||
Normal | 383 | 62 % | 152 | 69 % |
> ULN | 238 | 38 % | 69 | 31 % |
Platelet count - n (%) | ||||
Normal | 452 | 73 % | 159 | 72 % |
> ULN | 169 | 27 % | 62 | 28 % |
Albumin - n (%) | ||||
Normal | 391 | 63 % | 130 | 59 % |
< LLN | 230 | 37 % | 91 | 41 % |
Corrected serum calcium - n (%) | ||||
Normal | 421 | 68 % | 140 | 63 % |
> ULN | 200 | 32 % | 81 | 37 % |
Alkaline phosphatase - n (%) | ||||
Normal | 432 | 70 % | 152 | 69 % |
> ULN | 189 | 30 % | 69 | 31 % |
Lactate dehydrogenase - n (%) | ||||
Normal | 372 | 60 % | 179 | 81 % |
>1.5 times ULN | 249 | 40 % | 42 | 19 % |
Comorbidities - n (%) | ||||
0–1 | 356 | 57 % | 151 | 68 % |
>1 | 265 | 43 % | 67 | 30 % |
Time since RCC diagnosis | ||||
> one year | NA | NA | 16 | 7 % |
< one year | NA | NA | 204 | 92 % |